KBC Group
OCUL icon

KBC Group’s Ocular Therapeutix OCUL Stock Holding History

KBC Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63K Hold
6,462
– – ﹤0.01% 1636
2026
Q1 		$55K Hold
6,462
– – ﹤0.01% 1619
2025
Q4 		$78K Buy
+6,462
New +$78.5K ﹤0.01% 1448

Other funds holding OCUL

DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

KBC Group's OCUL Position: Q2 2026 in Review

KBC Group held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 6,462 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

KBC Group first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. The position peaked at $78K in Q4 2025. 78 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • KBC Group held 6,462 shares of Ocular Therapeutix worth $63K as of Q2 2026.
  • KBC Group left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1636 holding.
  • KBC Group first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • KBC Group's Ocular Therapeutix position peaked at $78K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.